Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138801 | Leukemia Research | 2009 | 12 Pages |
Abstract
For diagnosis and monitoring of Sézary syndrome flow cytometric quantification of CD7− and CD26− T-cells is widely used. Because antigen loss is a characteristic but not disease-specific finding we investigated the significance of this approach. Therefore we analyzed the prevalence of tumor cells in FACS-sorted CD7+/− as well as CD26+/− circulating T-cells applying a clone-specific qualitative and quantitative T-cell receptor PCR. Tumor cells varied considerably in the CD7+ and CD7− cell subset but were largely confined to the CD26− population. We conclude that quantification of CD26− T-cells reflects the tumor cell amount more accurate and should be preferred in the clinical setting.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Matthias Steinhoff, Sebastian Schöpp, Chalid Assaf, Marcus Muche, Marc Beyer, Wolfram Sterry, Ansgar Lukowsky,